Search Results - "Nigim, Fares"

Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion by Tateishi, Kensuke, Wakimoto, Hiroaki, Iafrate, A. John, Tanaka, Shota, Loebel, Franziska, Lelic, Nina, Wiederschain, Dmitri, Bedel, Olivier, Deng, Gejing, Zhang, Bailin, He, Timothy, Shi, Xu, Gerszten, Robert E., Zhang, Yiyun, Yeh, Jing-Ruey J., Curry, William T., Zhao, Dan, Sundaram, Sudhandra, Nigim, Fares, Koerner, Mara V.A., Ho, Quan, Fisher, David E., Roider, Elisabeth M., Kemeny, Lajos V., Samuels, Yardena, Flaherty, Keith T., Batchelor, Tracy T., Chi, Andrew S., Cahill, Daniel P.

“…Heterozygous mutation of IDH1 in cancers modifies IDH1 enzymatic activity, reprogramming metabolite flux and markedly elevating 2-hydroxyglutarate (2-HG)…”
Get full text

AS1411-Induced Growth Inhibition of Glioma Cells by Up-Regulation of p53 and Down-Regulation of Bcl-2 and Akt1 via Nucleolin by Cheng, Ye, Zhao, Gang, Zhang, Siwen, Nigim, Fares, Zhou, Guangtong, Yu, Zhiyun, Song, Yang, Chen, Yong, Li, Yunqian

“…AS1411 binds nucleolin (NCL) and is the first oligodeoxynucleotide aptamer to reach phase I and II clinical trials for the treatment of several cancers…”
Get full text

Immunomodulatory Arming Factors—The Current Paradigm for Oncolytic Vectors Relies on Immune Stimulating Molecules by Peters, Cole W. D., Nigim, Fares

“…The dogma of engineering oncolytic viral vectors has shifted from emphasizing the viral lysis of individual cancer cells to the recruitment and coordination of…”
Get full text

Updates on Oncolytic Virus Immunotherapy for Cancers by Peters, Cole, Grandi, Paola, Nigim, Fares

“…The 2018 annual Cambridge Healthtech Institute’s International Immuno-Oncology Summit in Boston, MA convened late August, and academic and industry researchers…”
Get full text

Emerging Medical Treatments for Meningioma in the Molecular Era by Nigim, Fares, Wakimoto, Hiroaki, Kasper, Ekkehard M, Ackermans, Linda, Temel, Yasin

“…Meningiomas are the most common type of primary central nervous system tumors. Approximately, 80% of meningiomas are classified by the World Health…”
Get full text

Shunting for hydrocephalus: analysis of techniques and failure patterns by Nigim, Fares, MD, Critchlow, Jonathan F., MD, Schneider, Benjamin E., MD, Chen, Clark, MD, PhD, Kasper, Ekkehard M., MD, PhD

“…Abstract Background Hydrocephalus is characterized by ventricular dilatation because of progressive accumulation of cerebrospinal fluid. Normal pressure…”
Get full text

Oncolytic viruses on the cusp of success?: proceedings of the 9th International Conference on Oncolytic Virus Therapeutics by Peters, Cole, Nigim, Fares, Chiocca, E Antonio, Rabkin, Samuel D

“…Boston, Massachusetts, was the site of the 9th International Conference on Oncolytic Virus Therapeutics held 13–16 June 2015. An overarching theme of the…”
Get full text

Multidisciplinary management improves survival at 1 year after surgical treatment for non-small-cell lung cancer: a propensity score-matched study by Tamburini, Nicola, Maniscalco, Pio, Mazzara, Sara, Maietti, Elisa, Santini, Alessandra, Calia, Nunzio, Stefanelli, Antonio, Frassoldati, Antonio, Santi, Ivan, Rinaldi, Rosa, Nigim, Fares, Righi, Riccardo, Pedrazzi, Stefania, Cavallesco, Giorgio

“…The management of patients affected by lung cancer requires the expertise of specialists from different disciplines. Although the advantages of…”
Get full text

Thymic Epithelial Tumors: Prognostic Significance and Relationship between Histology and the New TNM Staging System by Tamburini, Nicola, Maniscalco, Pio, Migliorelli, Andrea, Nigim, Fares, Quarantotto, Francesco, Maietti, Elisa, Cavallesco, Giorgio

“…This study aims to describe the relationship between the new tumor nodes metastasis (TNM) staging and World Health Organization (WHO) classification and to…”
Get more information

Blockade of transforming growth factor‐β signaling enhances oncolytic herpes simplex virus efficacy in patient‐derived recurrent glioblastoma models by Esaki, Shinichi, Nigim, Fares, Moon, Esther, Luk, Samantha, Kiyokawa, Juri, Curry, William, Cahill, Daniel P., Chi, Andrew S., Iafrate, A. John, Martuza, Robert L., Rabkin, Samuel D., Wakimoto, Hiroaki

“…Despite the current standard of multimodal management, glioblastoma (GBM) inevitably recurs and effective therapy is not available for recurrent disease. A…”
Get full text

1102: THE GHAJAR GUIDE by Nigim, Fares, Mueller, Camillo, Zinn, Pascal, Kasper, Ekkehard

Get full text

Granular cell tumor of the infundibulum: a systematic review of MR-radiography, pathology, and clinical findings by Polasek, Jessica B., Laviv, Yosef, Nigim, Fares, Rojas, Rafael, Anderson, Matthew, Varma, Hemant, Kasper, Ekkehard M.

“…Introduction Granular cell tumors (GCTs) of the infundibulum are rare in practice and literature, resulting in a lack of evidence-based standard of care. We…”
Get full text

CSIG-33. BETA 1 INTEGRIN INHIBITION IN HIGH-GRADE MENINGIOMA by Nigim, Fares, Gurtner, Alessandra, Brastianos, Priscilla, Cahill, Daniel, Rabkin, Samuel D, Martuza, Robert L, Carbonell, Shawn, Wakimoto, Hiroaki

“…High-grade meningiomas (HGM, World Health Organization classification grade II and III) have high relapse rates and poor clinical outcomes despite surgery and…”
Get full text

Targeting Hypoxia-Inducible Factor 1α in a New Orthotopic Model of Glioblastoma Recapitulating the Hypoxic Tumor Microenvironment by Nigim, Fares, Cavanaugh, Jill, Patel, Anoop P., Curry, William T., Esaki, Shin-ichi, Kasper, Ekkehard M., Chi, Andrew S., Louis, David N., Martuza, Robert L., Rabkin, Samuel D., Wakimoto, Hiroaki

“…Tissue hypoxia and necrosis represent pathophysiologic and histologic hallmarks of glioblastoma (GBM). Although hypoxia inducible factor 1α (HIF-1α) plays…”
Get full text

A new patient-derived orthotopic malignant meningioma model treated with oncolytic herpes simplex virus by Nigim, Fares, Esaki, Shin-Ichi, Hood, Michael, Lelic, Nina, James, Marianne F, Ramesh, Vijaya, Stemmer-Rachamimov, Anat, Cahill, Daniel P, Brastianos, Priscilla K, Rabkin, Samuel D, Martuza, Robert L, Wakimoto, Hiroaki

“…Higher-grade meningiomas (HGMs; World Health Organization grades II and III) pose a clinical problem due to high recurrence rates and the absence of effective…”
Get full text

Role of ventriculoperitoneal shunting in patients with neoplasms of the central nervous system: An analysis of 59 cases by NIGIM, FARES, CRITCHLOW, JONATHAN F, KASPER, EKKEHARD M

“…Approximately 1-5% of patients with cerebral metastasis and ~40% of patients with primary brain tumors suffer from hydrocephalus. These patients often exhibit…”
Get full text

MNGO-16ESTABLISHMENT OF A PATIENT - DERIVED ORTHOTOPIC MALIGNANT MENINGIOMA MODEL FOR THE DEVELOPMENT OF TARGETED THERAPY by Nigim, Fares, Rabkin, Samuel D., Brastianos, Priscilla, Ramesh, Vijaya, Cahill, Daniel, Santagata, Sandro, Martuza, Robert L., Wakimoto, Hiroaki

Get full text

A Monoclonal Antibody Against β1 Integrin Inhibits Proliferation and Increases Survival in an Orthotopic Model of High-Grade Meningioma by Nigim, Fares, Kiyokawa, Juri, Gurtner, Alessandra, Kawamura, Yoichiro, Hua, Lingyang, Kasper, Ekkehard M., Brastianos, Priscilla K., Cahill, Daniel P., Rabkin, Samuel D., Martuza, Robert L., Carbonell, W. Shawn, Wakimoto, Hiroaki

“…Background High-grade meningiomas (HGMs; World Health Organization [WHO] classification grade II and III) have high relapse rates and poor clinical outcomes…”
Get full text

AI-21HIF-1A TARGETING IN AN ORTHOTOPIC XENOGRAFT MODEL THAT RECAPITULATES THE HYPOXIC MICROENVIRONMENT OF GLIOBLASTOMA by Nigim, Fares, Cavanaugh, Jill, Patel, Anoop P., Curry, William T., Kasper, Ekkehard M., Chi, Andrew S., Martuza, Robert L., Rabkin, Samuel D., Wakimoto, Hiroaki

“…INTRODUCTION: Tissue hypoxia and necrosis represent a pathological hallmark of glioblastoma. Hypoxia inducible factor 1a (HIF-1a) plays crucial roles in the…”
Get full text

AI-21 HIF-1A TARGETING IN AN ORTHOTOPIC XENOGRAFT MODEL THAT RECAPITULATES THE HYPOXIC MICROENVIRONMENT OF GLIOBLASTOMA by Nigim, F., Cavanaugh, J., Patel, A. P., Curry, W. T., Kasper, E. M., Chi, A. S., Martuza, R. L., Rabkin, S. D., Wakimoto, H.

“…INTRODUCTION: Tissue hypoxia and necrosis represent a pathological hallmark of glioblastoma. Hypoxia inducible factor 1a (HIF-1a) plays crucial roles in the…”
Get full text